Oculis Holding AG (OCS) Interest Expenses (2022 - 2026)
Oculis Holding AG (OCS) posted quarterly Interest Expenses of -$42141.2 for Q1 2026, down 215.73% year-over-year from $36411.8 in Q1 2025, and up 6.44% quarter-over-quarter from -$45042.1 in Q4 2025.
Oculis Holding AG (OCS) Interest Expenses (2022 - 2026) Analysis & Trends
Oculis Holding AG's Interest Expenses history runs 5 years deep, the most recent figure standing at -$42141.2 for Q1 2026.
- In Q1 2026, Interest Expenses fell 215.73% year-over-year to -$42141.2; the TTM figure through Mar 2026 stood at -$467442.0 (down 1065.87% YoY), while the FY2025 annual figure was $1.0 million, up 38.32% from the prior year.
- Interest Expenses for Q1 2026 stood at -$42141.2, up from -$45042.1 in the prior quarter.
- The five-year high for Interest Expenses was $1.9 million in Q3 2022, with the low at -$1.7 million in Q2 2022.
- The 5-year median for Interest Expenses is -$12401.9 (2024), against an average of $175514.1.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses jumped 408.83% in 2024, then sank 2964.51% in 2025.
- Oculis Holding AG's Interest Expenses stood at $1.4 million in 2022, then sank by 98.61% to $18907.0 in 2023, then sank by 178.49% to -$14839.8 in 2024, then plunged by 203.52% to -$45042.1 in 2025, then advanced by 6.44% to -$42141.2 in 2026.
- Business Quant data shows OCS's Interest Expenses at -$42141.2 in Q1 2026, -$45042.1 in Q4 2025, and -$601302.7 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | 390,958.88 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 390,958.88 |
| Jun 30, 2026 | 390,958.88 |
| Mar 31, 2026 | -42,141.15 |
| Mar 31, 2026 | -42,141.15 |
| Dec 31, 2025 | -45,042.11 |
| Dec 31, 2025 | -45,042.11 |
| Sep 30, 2025 | -601,302.68 |
| Sep 30, 2025 | -601,302.68 |
| Jun 30, 2025 | 221,043.91 |
| Jun 30, 2025 | 221,043.91 |
| Mar 31, 2025 | -13,347.01 |
| Mar 31, 2025 | -13,347.01 |
| Dec 31, 2024 | -14,839.78 |
| Dec 31, 2024 | -14,839.78 |
| Sep 30, 2024 | -19,621.52 |
| Sep 30, 2024 | -19,621.52 |
| Jun 30, 2024 | 96,204.03 |
| Jun 30, 2024 | 96,204.03 |
| Mar 31, 2024 | -11,456.82 |
| Mar 31, 2024 | -11,456.82 |